Floatz logo

MONOCLONAL ANTIBODY BC8

Sickling Disorder Due to Hemoglobin S

Columbia Universitymonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

134 Active assets in the Sickling Disorder Due to Hemoglobin S cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB

View all 50 →

Same molecule, other indications

MONOCLONAL ANTIBODY BC8 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
B
Indicative ·
60 / 100
View asset →
Myelogenous LeukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →